Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients

被引:328
作者
Hunt, Kelly K. [1 ]
Yi, Min [1 ]
Mittendorf, Elizabeth A. [1 ]
Guerrero, Cynthia [1 ]
Babiera, Gildy V. [1 ]
Bedrosian, Isabelle [1 ]
Hwang, Rosa F. [1 ]
Kueret, Henry M. [1 ]
Ross, Merrick I. [1 ]
Meric-Bernstam, Funda [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
关键词
sentinel lymph node; neoadjuvant chemotherapy; false-negative rate; breast cancer; SURGICAL ADJUVANT BREAST; PREOPERATIVE CHEMOTHERAPY; BIOPSY; RECURRENCE; IMPACT; TUMOR; TRIAL; CYCLOPHOSPHAMIDE; METAANALYSIS; DOXORUBICIN;
D O I
10.1097/SLA.0b013e3181b8fd5e
中图分类号
R61 [外科手术学];
学科分类号
100210 [外科学];
摘要
Objective: Sentinel lymph node (SLN) surgery is widely used for nodal staging in early-stage breast cancer This study was pet-formed to evaluate the accuracy of SLN surgery for patients undergoing neoadjuvant chemotherapy versus patients undergoing surgery first. Summary Background Data: Controversy exists regarding the timing of SLN surgery in patients planned for neoadjuvant chemotherapy Proponents of SLN surgery after chemotherapy prefer a single surgical procedure with potential for fewer axillary dissections Opponents are early studies with low identification rates and high false-negative rates after chemotherapy. Methods: A total of 3746 patients with clinically node negative T1 -T3 breast cancer underwent SLN surgery front 1994 to 2001. Clinicopathologic data were reviewed and comparisons made between patients receiving neoadjuvant chemotherapy and those undergoing surgery first Results: Of the patients, 575 (15.3%) underwent SLN surgery after chemotherapy and 3171 (84.7%) underwent surgery first. Neoadjuvant patients were younger (51 vs. 57 years, P < 0.0001) and had more clinical T2-T3 tumors (87.3% vs 18.8%, P < 0.0001) at diagnosts SLN identification rates were 97.4% in the neoadjuvant group and 98.71% in the surgery first group (P = 0.017) False-negative rates were similar between groups (5/84 [5.9%] in neoadjuvant vs 22/542 [4.1%] in the surgery first group, P = 0.39) Analyzed by presenting T stage, there were fewer positive SLNs in the neoadjuvant group (T1: 12.7% vs 19.0%, P = 0 2; T2: 20.5% vs. 36.5%. P < 0.0001. T3. 30.4% vs. 51.4%, P = 0.04). Adjusting for clinical stage revealed no differences in local-regional recurrences, disease-free or overall survival between groups Conclusions: SLN surgery after chemotherapy is as accurate for axillary staging as SLN surgery prior to chemotherapy. SIN surgery after chemotherapy results in fewer positive SLNs and decreases unnecessary axillary dissections
引用
收藏
页码:558 / 566
页数:9
相关论文
共 31 条
[1]
[Anonymous], 2002, AJCC cancer staging manual, P223, DOI [10.1007/978-1-4757-3656-4, DOI 10.1007/978-1-4757-3656-4]
[2]
Impact on regional recurrence and survival of axillary surgery in women with node-negative primary breast cancer [J].
Axelsson, C. K. ;
Duering, M. ;
Christiansen, P. M. ;
Wamberg, P. A. ;
Soe, K. L. ;
Moller, S. .
BRITISH JOURNAL OF SURGERY, 2009, 96 (01) :40-46
[3]
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27 [J].
Bear, HD ;
Anderson, S ;
Brown, A ;
Smith, R ;
Mamounas, EP ;
Fisher, B ;
Margolese, R ;
Theoret, H ;
Soran, A ;
Wickerham, DL ;
Wolmark, N .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4165-4174
[4]
Axillary-conserving surgery is facilitated by neoadjuvant chemotherapy of breast cancer [J].
Beatty, J. David ;
Precht, Lisa M. ;
Lowe, Kimberly ;
Atwood, Mary .
AMERICAN JOURNAL OF SURGERY, 2009, 197 (05) :637-642
[5]
Bedrosian I, 2000, CANCER, V88, P2540, DOI 10.1002/1097-0142(20000601)88:11<2540::AID-CNCR16>3.0.CO
[6]
2-A
[7]
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer [J].
Breslin, TM ;
Cohen, L ;
Sahin, A ;
Fleming, JB ;
Kuerer, HM ;
Newman, LA ;
Delpassand, ES ;
House, R ;
Ames, FC ;
Feig, BW ;
Ross, MI ;
Singletary, SE ;
Buzdar, AU ;
Hortobagyi, GN ;
Hunt, KK .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (20) :3480-3486
[8]
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen [J].
Buzdar, Aman U. ;
Valero, Vicente ;
Ibrahim, Nuhad K. ;
Francis, Deborah ;
Broglio, Kristine R. ;
Theriault, Richard L. ;
Pusztai, Lajos ;
Green, Marjorie C. ;
Singletary, Sonja E. ;
Hunt, Kelly K. ;
Sahin, Aysegul A. ;
Esteva, Francisco ;
Symmans, William F. ;
Ewer, Michael S. ;
Buchholz, Thomas A. ;
Hortobagyi, Gabriel N. .
CLINICAL CANCER RESEARCH, 2007, 13 (01) :228-233
[9]
Role for Sentinel Lymph Node Dissection in the Management of Large (≥5 cm) Invasive Breast Cancer [J].
Mathew H. Chung ;
Wei Ye ;
Armando E. Giuliano .
Annals of Surgical Oncology, 2001, 8 (9) :688-692
[10]
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy for Advanced Breast Cancer: Results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French Prospective Multicentric Study [J].
Classe, Jean-Marc ;
Bordes, Virginie ;
Campion, Loic ;
Mignotte, Herve ;
Dravet, Francois ;
Leveque, Jean ;
Sagan, Christine ;
Dupre, Pierre Francois ;
Body, Gilles ;
Giard, Sylvia .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :726-732